Beijing Bio-Cybernaut Biomedical Engineering

Beijing Bio-Cybernaut Biomedical Engineering is a pioneering Chinese biotechnology company specializing in gene therapy for cancer. Founded in 1998 by Dr. Peng Zhaohui, the company developed Gendicine (Ad-p53), which in 2003 became the world's first gene therapy product to receive regulatory approval. Gendicine utilizes a recombinant adenoviral vector to deliver the p53 tumor suppressor gene into cancer cells, inducing apoptosis and inhibiting tumor growth. The company focuses on the research, development, and industrialization of gene-based medicines, leveraging its proprietary adenoviral platform to target various solid tumors. Beijing Bio-Cybernaut remains a key player in the Chinese gene therapy landscape, with ongoing clinical research into expanded indications for its flagship product.